PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16616494-1	2006	The preparation of the sulfoxide analogues 2 and 4, and their enantiomeric pure forms is discussed as well as their potential to act as prodrugs to the potent and selective sulfone-containing COX-2 inhibitors rofecoxib and etoricoxib.	Etoricoxib	223-233	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	192-197	
26857505-9	2016	Administration of etoricoxib in cAD rats resulted in recovery of memory impairments, neurodegeneration and neuroinflammation in hippocampus and inhibition of cox-2 and PGE2 levels in hippocampus.	Etoricoxib	18-28	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	158-163	
31495059-0	2020	The COX-2 inhibitor etoricoxib reduces experimental osteoarthritis and nociception in rats: The roles of TGF-beta1 and NGF expressions in chondrocytes.	Etoricoxib	20-30	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	4-9	
31495059-2	2020	Etoricoxib, a highly selective cyclooxygenase (COX)-2 inhibitor which can reduce postoperative pain after orthopedic surgery.	Etoricoxib	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	31-53	
30970055-1	2019	In the present study we compared the effects of the selective COX-2 inhibitor etoricoxib with those of the classical non-selective NSAID diclofenac on the inflammatory process and alveolar bone loss in an experimental model of periodontitis in rats.	Etoricoxib	78-88	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	62-67	
30048759-0	2018	Effects of the highly COX-2-selective analgesic NSAID etoricoxib on the rate of orthodontic tooth movement and cranial growth.	Etoricoxib	54-64	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	22-27	
30048759-2	2018	The highly COX-2-selective NSAID etoricoxib has shown a favorable side effect profile and excellent analgesic efficacy, particularly for dental and orthodontic pain, surpassing the current standard analgesic in orthodontics, acetaminophen.	Etoricoxib	33-43	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	11-16	
26857505-7	2016	administration of 3 different doses of etoricoxib, a cox 2 inhibitor.	Etoricoxib	39-49	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	53-58	
26880859-3	2016	Therefore, the present study was designed to investigate the role of cox-2 on the anxiety behavior (response to novelty in an elevated open field space) of cAD by inhibiting it with three different doses (10, 20, and 30 mg) of etoricoxib (a cox-2 blocker) in two time points (14 and 21 days).	Etoricoxib	227-237	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	69-74	
25701797-0	2015	Antiepileptogenic effects of the selective COX-2 inhibitor etoricoxib, on the development of spontaneous absence seizures in WAG/Rij rats.	Etoricoxib	59-69	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	43-48	
26689653-2	2016	In this work, we explored Etoricoxib (COX-2 inhibitor)-loaded Poly caprolactone (PCL) microparticles (MPs) as a potential IA-DDS.	Etoricoxib	26-36	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	38-43	
25701797-5	2015	We studied whether early long-term treatment (17 consecutive weeks starting from 45 days postnatal age) with the non-steroidal anti-inflammatory drug etoricoxib (10 mg/kg/day per os), a selective COX-2 inhibitor, was able to prevent/reduce the development of absence seizures in WAG/Rij rats, a recognized animal model of absence epilepsy and epileptogenesis.	Etoricoxib	150-160	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	196-201	
21198287-0	2010	Anti-proliferative and apoptotic effects of etoricoxib, a selective COX-2 inhibitor, on 1,2-dimethylhydrazine dihydrochloride-induced colon carcinogenesis.	Etoricoxib	44-54	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	68-73	
26236425-10	2015	Furthermore, etoricoxib prevented increase of COX-2 gene expression and ALT and AST levels.	Etoricoxib	13-23	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	46-51	
25068826-7	2014	Etoricoxib reduced, in a dose-dependent manner, levels of MDA, MPO and COX-2 that normally rise with I/R in rat kidney tissues.	Etoricoxib	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	71-76	
24888933-1	2014	AIM: This study is a biochemical investigation of the effect of etoricoxib, a selective cyclooxygenase (COX)-2 inhibitor, on ischemia/reperfusion (I/R) injury experimentally induced in rat ovaries.	Etoricoxib	64-74	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	88-110	
20694294-2	2010	Therefore, the potential ability of Etoricoxib, a selective cycloxygenase-2(COX-2) inhibitor and Diclofenac, a preferential COX-2 inhibitor are considered in the chemoprevention of 1, 2-dimethylhydrazine (DMH) induced colon carcinogenesis in rat model.	Etoricoxib	36-46	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	76-81	
22991065-0	2013	Role of cytokines in experimentally induced lung cancer and chemoprevention by COX-2 selective inhibitor, etoricoxib.	Etoricoxib	106-116	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	79-84	
22991065-1	2013	This study explored the role of pro- and anti-inflammatory cytokines in dimethyl benz(a)anthracene (DMBA)-induced lung cancer and its subsequent correction with a COX-2 inhibitory NSAID, etoricoxib.	Etoricoxib	187-197	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	163-168	
21308296-4	2010	Ketorolac is a non-selective NSAID which, at low doses, has a preferential COX-1 inhibitory effect and etoricoxib is a new selective COX-2 inhibitor.	Etoricoxib	103-113	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	133-138	
19109739-2	2008	Here, we compared etoricoxib, a specific COX-2 inhibitor, with other cyclooxygenase inhibitors on articular incapacitation, edema, leukocyte migration, and gastric damage, in a model of LPS-induced reactive arthritis in rats.	Etoricoxib	18-28	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	41-46	
19721906-1	2009	The present study was designed to investigate the effects of a selective COX-2 inhibitor, etoricoxib in rats on the hematological and toxicity parameters in colon and kidney at two different doses of the drug, one within the therapeutic anti-inflammatory range as based on the reported ED50 value (Eto-1) while the other at ten times higher (Eto-2), relative to the toxicity studies which have not been reported so far.	Etoricoxib	90-100	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	73-78	
19109739-10	2008	CONCLUSION: The present results suggest that the selective COX-2 inhibitor etoricoxib could be a better option than non-selective COX inhibitors, since it presented a potent inhibitory effect on the clinical signals and also a potent inhibition on cell migration.	Etoricoxib	75-85	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	59-64	
19105535-1	2008	The present study was designed to investigate the effects of a selective cycloogenase-2 (COX-2) inhibitor, etoricoxib, on the membrane-specific enzymes, lipid composition, and changes in fluidity parameters of rat colonic plasma membrane.	Etoricoxib	107-117	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	89-94	
19105535-8	2008	It is concluded that etoricoxib, a new generation COX-2 inhibitor (called the coxibs), appeared to be a safe nonsteroidal anti-inflammatory drug (NSAID) in the colonic membranes.	Etoricoxib	21-31	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	50-55	
17701021-1	2007	This study has evaluated the anti-inflammatory and analgesic responses of etoricoxib, a selective COX-2 non-steroidal anti-inflammatory drug combined with misoprostol in pre-clinical assays.	Etoricoxib	74-84	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	98-103